title: [Bridging posttraumatic bony defects. Established and new methods].
abstract: Bony defects as a result of injury or disease can be caused by a variety of conditions such as acute injury, fall fractures in osteoporotic patients or tumours and congenital malformations of the musculoskeletal system which necessitate the resection of affected parts of the bone. This results in a multitude of defects concerning localisation and specificity as well as a number of conditions involving both hard and soft tissue structures and various situations of different patients. A reasonable classification of defects which is relevant for practical purposes includes four basic types: defects of the spine, metaphyseal defects as well as partial and complete diaphyseal defects of long bones. A variety of options exists for the treatment of these conditions. The aim of all efforts is to reinstall the integrity of affected structures long-lastingly and dependably and at the same time guarantee the normal function of joints involved. In addition to classical treatment strategies which involve the use of autogenous and allogenous corticocancellous bone grafts a great number of bone substitute materials can also be used. Further options lie in complex reconstructive methods such as the transport of whole segments or the transplantation of vascularised bone grafts. The field of new regenerative strategies including tissue engineering as well as stem cell and gene therapy holds great promise for the future. The aim of this review is to derive a ranking from the evaluation of biological and mechanical characteristics for the treatment of posttraumatic defects.
authors.affiliation: Experimentelle Chirurgie und Regenerative Medizin, Chirurgische Klinik Innenstadt Klinikum der Universität, Nussbaumstrasse 20, 80336 München. Deutschland. Matthias.Schieker@med.uni-muenchen.de
authors.forename: M
authors.initials: M
authors.lastname: Schieker
authors.forename: W
authors.initials: W
authors.lastname: Mutschler
mesh_terms: D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000502:physiology; D001859:Bone Neoplasms / Q000556:secondary / Q000601:surgery*; D001861:Bone Regeneration; D018786:Bone Substitutes / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000009:adverse effects; D018483:Diaphyses / Q000601:surgery; D016267:External Fixators; D005260:Female; D005544:Forecasting; D050723:Fractures, Bone / Q000000981:diagnostic imaging / Q000601:surgery*; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications; D044968:Regenerative Medicine; D016103:Spinal Fractures / Q000000981:diagnostic imaging / Q000601:surgery*; D013123:Spinal Fusion; D013125:Spinal Neoplasms / Q000556:secondary / Q000601:surgery*; D033581:Stem Cell Transplantation; D023822:Tissue Engineering; D014057:Tomography, X-Ray Computed
chemical_list: D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes